These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21974949)

  • 1. Discovery of a new class of glucosylceramide synthase inhibitors.
    Koltun E; Richards S; Chan V; Nachtigall J; Du H; Noson K; Galan A; Aay N; Hanel A; Harrison A; Zhang J; Won KA; Tam D; Qian F; Wang T; Finn P; Ogilvie K; Rosen J; Mohan R; Larson C; Lamb P; Nuss J; Kearney P
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6773-7. PubMed ID: 21974949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimization of pyridazinone series of glucan synthase inhibitors.
    Kuang R; Wu H; Ting PC; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Herr RJ; Zych AJ; Yang J; Lam SQ; Jenkins DM; Sakwa SA; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5268-71. PubMed ID: 22818082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of an inhibitor of glucosylceramide synthase.
    Richards S; Larson CJ; Koltun ES; Hanel A; Chan V; Nachtigall J; Harrison A; Aay N; Du H; Arcalas A; Galan A; Zhang J; Zhang W; Won KA; Tam D; Qian F; Wang T; Finn P; Ogilvie K; Rosen J; Aoyama R; Plonowski A; Cancilla B; Bentzien F; Yakes M; Mohan R; Lamb P; Nuss J; Kearney P
    J Med Chem; 2012 May; 55(9):4322-35. PubMed ID: 22497444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-Alkyl 5-membered ring imino sugars as new potent cytotoxic glucosylceramide synthase inhibitors.
    Faugeroux V; Génisson Y; Andrieu-Abadie N; Colié S; Levade T; Baltas M
    Org Biomol Chem; 2006 Dec; 4(24):4437-9. PubMed ID: 17268635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
    Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimization of a sulfonylurea-based piperazine pyridazinone series of glucan synthase inhibitors.
    Zych AJ; Lam SQ; Jenkins DM; Herr RJ; Ting PC; Lee JF; Kuang R; Wu H; Kim DW; Aslanian RG; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4896-9. PubMed ID: 22687744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.
    Heasley BH; Pacofsky GJ; Mamai A; Liu H; Nelson K; Coti G; Peel MR; Balkovec JM; Greenlee ML; Liberator P; Meng D; Parker DL; Wilkening RR; Apgar JM; Racine F; Hsu MJ; Giacobbe RA; Kahn JN
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6811-6. PubMed ID: 22672801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.
    Shimamura K; Nagumo A; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
    Eur J Pharmacol; 2010 Mar; 630(1-3):34-41. PubMed ID: 20045404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors.
    Mizutani T; Ishikawa S; Nagase T; Takahashi H; Fujimura T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N
    J Med Chem; 2009 Nov; 52(22):7289-300. PubMed ID: 19883081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.
    Zhou G; Ting PC; Aslanian R; Cao J; Kim DW; Kuang R; Lee JF; Schwerdt J; Wu H; Herr RJ; Zych AJ; Yang J; Lam S; Wainhaus S; Black TA; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 May; 21(10):2890-3. PubMed ID: 21489787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?
    Norris-Cervetto E; Butters TD; Martin C; Modok S; Dwek RA; Callaghan R
    Eur J Pharmacol; 2006 Jan; 530(3):195-204. PubMed ID: 16403499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.
    Kley JT; Mack J; Hamilton B; Scheuerer S; Redemann N
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5924-7. PubMed ID: 21873051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors.
    Yun W; Ahmad M; Chen Y; Gillespie P; Conde-Knape K; Kazmer S; Li S; Qian Y; Taub R; Wertheimer SJ; Whittard T; Bolin D
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7205-9. PubMed ID: 22001092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Evaluation of Hybrid Structures Composed of Two Glucosylceramide Synthase Inhibitors.
    van den Berg RJ; van Rijssel ER; Ferraz MJ; Houben J; Strijland A; Donker-Koopman WE; Wennekes T; Bonger KM; Ghisaidoobe AB; Hoogendoorn S; van der Marel GA; Codée JD; Overkleeft HS; Aerts JM
    ChemMedChem; 2015 Dec; 10(12):2042-62. PubMed ID: 26492941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, anti-fungal and 1,3-β-D-glucan synthase inhibitory activities of caffeic and quinic acid derivatives.
    Ma CM; Abe T; Komiyama T; Wang W; Hattori M; Daneshtalab M
    Bioorg Med Chem; 2010 Oct; 18(19):7009-14. PubMed ID: 20813534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
    Bonnefous C; Payne JE; Roppe J; Zhuang H; Chen X; Symons KT; Nguyen PM; Sablad M; Rozenkrants N; Zhang Y; Wang L; Severance D; Walsh JP; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
    J Med Chem; 2009 May; 52(9):3047-62. PubMed ID: 19374401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.
    Ting PC; Kuang R; Wu H; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1819-22. PubMed ID: 21316223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors.
    Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Darji B; Siriki Y; Bandyopadhyay D; Joharapurkar A; Kshirsagar S; Patel H; Shaikh M; Sairam KV; Patel P
    ChemMedChem; 2011 Jun; 6(6):1011-6. PubMed ID: 21506278
    [No Abstract]   [Full Text] [Related]  

  • 19. 1,2-Dihydro-4-quinazolinamines: potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo.
    Tinker AC; Beaton HG; Boughton-Smith N; Cook TR; Cooper SL; Fraser-Rae L; Hallam K; Hamley P; McInally T; Nicholls DJ; Pimm AD; Wallace AV
    J Med Chem; 2003 Mar; 46(6):913-6. PubMed ID: 12620067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sulfobutyl ether beta-cyclodextrin as a vehicle for D-threo-1-phenyl-2-decanoylamino-3-morpholinopropanol-relat ed glucosylceramide synthase inhibitors.
    Abe A; Gregory S; Lee L; Shayman JA
    Anal Biochem; 2000 Dec; 287(2):344-7. PubMed ID: 11112286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.